Lightpoint Medical, a Rickmansworth, United Kingdom- and Cambridge, Massachusetts-based medical device company specializing in imaging technologies, received an R01 grant of $2.6M from the US National Cancer Institute.
The funding will support clinical trials of Lightpoint’s EnLight™ molecular imaging technology in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center (MSK).
Led by Dr David Tuch, Founder and CEO, Lightpoint has developed the EnLight™ fiberscope system, which uses molecular imaging technology to reveal microscopic cancer deposits and promises to enable surgeons to identify cancerous tissue.
The company, which will collaborate with MSK’s Drs Jan Grimm and Nadeem Abu-Rustum to carry out this important research, is backed by business angels and other private investors.
FinSMEs
06/08/2015